Merck "progressing well" with turnaround plan

Analysts say Merck's latest earnings report shows the company's turnaround plan is working, aided by cost-cutting and sales of new medicines, such as its Gardasil vaccine against cervical cancer. Merck also reported it added $210 million to its reserve for defending against Vioxx lawsuits, which now number 26,950.

View Full Article in:

NYTimes.com · Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC